Ionis Pharmaceuticals, Inc. (IONS)
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.
Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
Ionis Pharmaceuticals (IONS) has appreciated ~25% since my last upgrade, reflecting strong momentum. This article spotlights Olezarsen, Ionis's wholly owned molecule, as a key driver of future upside. Recent approvals and upcoming catalysts underpin the bullish investment thesis for IONS.
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. ( IONS ) Stifel 2025 Healthcare Conference November 13, 2025 8:00 AM EST Company Participants Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Elizabeth L. Hougen - Executive VP of Finance & CFO Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Paul Matteis Stifel, Nicolaus & Company, Incorporated, Research Division Good morning.
Ionis Pharmaceuticals, Inc. (IONS) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia Transcript
Ionis Pharmaceuticals, Inc. ( IONS ) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia November 8, 2025 3:00 PM EST Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sotirios Tsimikas - Senior Vice President of Global Cardiovascular Development Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Conference Call Participants Jay Olson - Oppenheimer & Co. Inc., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Denis Reznik - Raymond James & Associates, Inc., Research Division Zaki Molvi - Jefferies LLC, Research Division Tommie Reerink - Goldman Sachs Group, Inc., Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Myles Minter - William Blair & Company L.L.C.
Ionis: Near-Term Launches With Blockbuster Potential Boosts Upside Despite Stock Rally
Ionis Pharmaceuticals maintains a Buy rating as its transformation to a commercial company accelerates, driven by wholly-owned product launches and revenue growth. Q3 results highlight a revenue shift toward Ionis-owned drugs, with Tryngolza outperforming and Dawnzera launching as a differentiated HAE prophylactic. Olezarsen's strong Phase 3 data in sHTG positions IONS for a blockbuster opportunity, despite market competition and ongoing patent litigation with Arrowhead.
Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?
Ionis Pharmaceuticals, Inc. has surged on strong phase-3 trial data and a robust pipeline, but much optimism is already priced in. IONS boasts recent drug launches (Wainua, Tryngolza, Dawnzera) with significant revenue potential, offsetting declining Spinraza royalties amid rising competition. Financials show strong cash reserves but ongoing cash burn; valuation is stretched with a high price/sales ratio and dilution risk.
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
IONS' Q3 results top estimates as robust Tryngolza and Wainua sales drive revenue growth. The company raises its 2025 outlook for the third time this year.
Ionis Pharmaceuticals, Inc. (IONS) Q3 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. ( IONS ) Q3 2025 Earnings Call October 29, 2025 11:30 AM EDT Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Richard S.
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.95 per share a year ago.
